All In Biotech

Drug Trial Radar · NCT06741150

NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.

Safety and Efficacy Study of NWRD09 in HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.

Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

18

Planned (sponsor's estimate)

Start

Jun 24, 2024

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open label, two cohorts, multi-center clinical study to evaluate the safety and efficacy of HPV-16 targeted mRNA vaccine (NWRD09) in HPV-16 positive and HPV-16 related cervical, vaginal, and vulvar intraepithelial neoplasia (LSIL and HSIL) patients (cohort A) and HPV-16 related cervical cancer patients (cohort B).

Conditions

  • Intraepithelial Neoplasia
  • Cervical Cancer

Interventions

  • NWRD09 administered by intramuscular injectionBiological

    Intramuscular injection administration was carried out according to the protocol design.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety(Cohort A and B)Time frame: Within 21 days of the first dosing
  2. Dose-limiting toxicity (DLT) (Cohort A and B)Time frame: Within 21 days of the first dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.